Previous Issue
Volume 17, April
 
 

Pharmaceutics, Volume 17, Issue 5 (May 2025) – 48 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Section
Select all
Export citation of selected articles as:
19 pages, 1197 KiB  
Article
Application of Theoretical Solubility Calculations and Thermal and Spectroscopic Measurements to Guide the Processing of Triamcinolone Acetonide by Hot-Melt Extrusion
by Pedro A. Granados, Idejan P. Gross, Patrícia Medeiros-Souza, Livia L. Sá-Barreto, Guilherme M. Gelfuso, Tais Gratieri and Marcilio Cunha-Filho
Pharmaceutics 2025, 17(5), 586; https://doi.org/10.3390/pharmaceutics17050586 (registering DOI) - 29 Apr 2025
Abstract
Background/Objectives: Triamcinolone acetonide (TA), a poorly water-soluble corticosteroid, presents formulation challenges due to limited membrane permeability. This study aimed to identify suitable drug–polymer–plasticizer systems for TA using combined theoretical and experimental methods. Methods: Using Hansen solubility parameters, seven hot-melt extrusion (HME)-grade [...] Read more.
Background/Objectives: Triamcinolone acetonide (TA), a poorly water-soluble corticosteroid, presents formulation challenges due to limited membrane permeability. This study aimed to identify suitable drug–polymer–plasticizer systems for TA using combined theoretical and experimental methods. Methods: Using Hansen solubility parameters, seven hot-melt extrusion (HME)-grade polymers and four plasticizers were initially screened for miscibility with TA. Based on Δδt values, four polymers—Eudragit® L100 (EUD), Parteck® MXP (PVA), Plasdone® S-630 (PVPVA), and Aquasolve™ AS-MG (HPMCAS)—along with triethyl citrate (TEC), were selected for experimental evaluation. Differential scanning calorimetry, thermogravimetric analysis, and Fourier transform infrared spectroscopy assessed thermal behavior, miscibility, and chemical compatibility. Results: Amorphous TA content was highest with EUD (81.1%), followed by PVA (67.5%), PVPVA (45.6%), and HPMCAS (8.5%). Thermal incompatibility and TEC evaporation were observed in PVA, PVPVA, and HPMCAS systems. FTIR suggested TEC should be avoided in melt-based formulations with PVA and PVPVA due to PVA degradation and partial TA oxidation. No significant interactions were detected in HPMCAS samples heated to 220 °C, aligning with theoretical predictions. In contrast, the EUD–TEC system showed limited chemical reactivity and maintained TA’s structural integrity. Infrared bands at 1758 and 1802 cm−1 indicated minor anhydride formation above 160 °C with partial TEC evaporation. Conclusions: EUD/TEC were identified as a promising combination for the HME processing of TA. This work supports the rational formulation of stable amorphous systems for thermolabile drugs with poor solubility. Full article
(This article belongs to the Special Issue Pharmaceutical Solids: Advanced Manufacturing and Characterization)
Show Figures

Figure 1

17 pages, 938 KiB  
Article
Impact of Pharmacogenetics on High-Dose Methotrexate Toxicity in Pediatric Oncology
by Luciana Maria Marangoni-Iglecias, Almudena Sánchez-Martin, Laura Elena Pineda-Lancheros, Yasmín Cura, Noelia Marquez-Pete, José María Gálvez-Navas, Nerea Báez-Gutiérrez, Adrián Manuel de La Jara-Vera, Emilia Urrutia-Maldonado, Cristina Pérez-Ramírez and Alberto Jiménez-Morales
Pharmaceutics 2025, 17(5), 585; https://doi.org/10.3390/pharmaceutics17050585 (registering DOI) - 29 Apr 2025
Abstract
Background: Childhood cancers represent a heterogeneous group of malignancies and remain one of the leading causes of mortality among children under 14 years of age, ranking second only to accidental injuries, and fourth among individuals aged 15 to 19 years. Despite notable [...] Read more.
Background: Childhood cancers represent a heterogeneous group of malignancies and remain one of the leading causes of mortality among children under 14 years of age, ranking second only to accidental injuries, and fourth among individuals aged 15 to 19 years. Despite notable improvements in cure rates, a substantial proportion of patients experience acute or long-term toxicities associated with treatment. Methotrexate (MTX), a chemotherapeutic agent, has been employed effectively for over six decades in the management of pediatric malignancies. High-dose methotrexate constitutes a cornerstone of pediatric cancer therapy; however, its clinical utility is frequently constrained by dose-limiting toxicities. Objectives: This study investigates the impact of genetic polymorphisms in genes involved in nucleotide metabolism, as well as methotrexate and folate metabolic pathways, on treatment-related toxicity in childhood cancer. Methods: Using real-time polymerase chain reaction, 14 polymorphisms across 12 genes were analyzed in a cohort of 107 patients. Toxicity was assessed according to the Common Terminology Criteria for Adverse Events v. 5.0. Results: Multivariate logistic regression analysis revealed that the male sex (p = 0.3) and the AA genotype of MTHFD1 rs2236225 were associated with grade III–IV gastrointestinal toxicity (p = 0.03), while the A allele of MTHFR rs1801133 and the AA genotype of GSTP1 rs1695 were associated with grade I–IV hematologic toxicity (p < 0.01 and p = 0.02, respectively). Conclusions: High-dose methotrexate (HDMTX) is a critical agent in the treatment of childhood cancers. Our findings suggest that genetic polymorphisms within methotrexate and folate metabolic pathways may serve as potential predictive biomarkers of treatment-related toxicity. Full article
(This article belongs to the Section Pharmacokinetics and Pharmacodynamics)
Show Figures

Figure 1

29 pages, 8212 KiB  
Review
The Future of Alopecia Treatment: Plant Extracts, Nanocarriers, and 3D Bioprinting in Focus
by Rana E. Elnady, Manar S. Abdon, Hagar R. Shaheen, Reem M. Eladawy, Yasmena O. Azar and Seham M. Al Raish
Pharmaceutics 2025, 17(5), 584; https://doi.org/10.3390/pharmaceutics17050584 (registering DOI) - 29 Apr 2025
Abstract
Alopecia is a concerning dermatological issue and is also known as alopecia. This disease can affect men and women, influencing their confidence and appearance. It targets the scalp or any area of the entire body. Alopecia has become widespread worldwide over the years [...] Read more.
Alopecia is a concerning dermatological issue and is also known as alopecia. This disease can affect men and women, influencing their confidence and appearance. It targets the scalp or any area of the entire body. Alopecia has become widespread worldwide over the years and has many types and different causes: hereditary, hormonal, immunological, therapeutic, or psychological. This review will present a comprehensive study of the physiological structure of hair and the different growth and shedding phases. It discusses using nano-drug delivery systems that contain natural substances of plant origin, which are effective, less harmful compared to current treatments, and help avoid adverse effects. This review also covers the latest trends in treating alopecia, including drug delivery systems, the materials and methods used to prepare these systems, three-dimensional (3D) bioprinting strategies, and plant extracts that may be utilized for treatment in the coming years. Full article
(This article belongs to the Section Nanomedicine and Nanotechnology)
Show Figures

Figure 1

30 pages, 4009 KiB  
Review
Ethosome-Based Transdermal Drug Delivery: Its Structural Components, Preparation Techniques, and Therapeutic Applications Across Metabolic, Chronic, and Oncological Conditions
by Rashed M. Almuqbil and Bandar Aldhubiab
Pharmaceutics 2025, 17(5), 583; https://doi.org/10.3390/pharmaceutics17050583 (registering DOI) - 29 Apr 2025
Abstract
Transdermal drug delivery systems (TDDSs) provide a non-invasive alternative to oral and parenteral routes, delivering drugs into the bloodstream while avoiding gastrointestinal degradation and first-pass metabolism. Despite benefits like enhanced bioavailability and patient compliance, the stratum corneum limits drug permeation. Ethosomes overcome the [...] Read more.
Transdermal drug delivery systems (TDDSs) provide a non-invasive alternative to oral and parenteral routes, delivering drugs into the bloodstream while avoiding gastrointestinal degradation and first-pass metabolism. Despite benefits like enhanced bioavailability and patient compliance, the stratum corneum limits drug permeation. Ethosomes overcome the stratum corneum barrier with superior flexibility and permeability compared to liposomes. Ethanol disrupts the skin’s lipid bilayer, enabling deep penetration and efficient drug delivery. Ethosomes offer high entrapment efficiency and stability, delivering both hydrophilic and lipophilic drugs. However, challenges like stability optimization and clinical translation persist. This review examines the structural components, preparation methods, and therapeutic applications of ethosomes in metabolic and chronic diseases, including diabetes, cardiovascular diseases, neurodegenerative disorders, arthritis, and cancers. Moreover, it highlights the potential of ethosomes to revolutionize TDDSs for managing chronic and metabolic diseases, providing a foundation for further research and clinical development. Full article
(This article belongs to the Special Issue Application of Nanomedicine in Metabolic and Chronic Diseases)
Show Figures

Graphical abstract

2 pages, 596 KiB  
Correction
Correction: Rasool et al. Non-Invasive Delivery of Nano-Emulsified Sesame Oil-Extract of Turmeric Attenuates Lung Inflammation. Pharmaceutics 2020, 12, 1206
by Sahibzada Tasleem Rasool, Rajasekhar Reddy Alavala, Umasankar Kulandaivelu and Nagaraja Sreeharsha
Pharmaceutics 2025, 17(5), 582; https://doi.org/10.3390/pharmaceutics17050582 (registering DOI) - 29 Apr 2025
Abstract
In the original publication, there was a mistake in Figure 8 as published [...] Full article
Show Figures

Figure 8

24 pages, 2668 KiB  
Review
Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral Infections
by Mohamed Halawa, Ramez M. Rashad ElSayed, Tope Aderibigbe, Precious M. Newman, Briana E. Reid and Valerie J. Carabetta
Pharmaceutics 2025, 17(5), 581; https://doi.org/10.3390/pharmaceutics17050581 (registering DOI) - 28 Apr 2025
Viewed by 56
Abstract
Biosimilars represent medicinal products that exhibit a high degree of similarity to an already sanctioned reference biologic agent, with negligible clinically significant disparities concerning safety, purity, or potency. These therapeutic modalities are formulated as economically viable substitutes for established biologics, thereby facilitating increased [...] Read more.
Biosimilars represent medicinal products that exhibit a high degree of similarity to an already sanctioned reference biologic agent, with negligible clinically significant disparities concerning safety, purity, or potency. These therapeutic modalities are formulated as economically viable substitutes for established biologics, thereby facilitating increased accessibility to sophisticated treatments for a range of medical conditions, including infectious diseases caused by bacterial, fungal, and viral pathogens. The current landscape of biosimilars includes therapeutic proteins, such as monoclonal antibodies, antimicrobial peptides, antiviral peptides, and antifungal peptides. Here, we discuss the obstacles inherent in the development of biosimilars, including the rapid mutation rates of pathogens. Furthermore, we discuss innovative technologies within the domain, including antibody engineering, synthetic biology, and cell-free protein synthesis, which exhibit potential for improving the potency and production efficiency of biosimilars. We end with a prospective outlook to highlight the importance and capacity of biosimilars to tackle emerging infectious diseases, highlighting the imperative need for ongoing research and financial commitment. Full article
(This article belongs to the Special Issue State of the Art of Membrane Active Peptides, 2nd Edition)
Show Figures

Graphical abstract

14 pages, 250 KiB  
Review
Unraveling the Mechanisms, Clinical Impact, Comparisons, and Safety Profiles of Slow-Release Therapies in Glaucoma
by Marco Zeppieri, Caterina Gagliano, Daniele Tognetto, Mutali Musa, Federico Bernardo Rossi, Angelo Greggio, Giuliano Gualandi, Alessandro Galan and Silvia Babighian
Pharmaceutics 2025, 17(5), 580; https://doi.org/10.3390/pharmaceutics17050580 (registering DOI) - 28 Apr 2025
Viewed by 41
Abstract
Glaucoma, a primary cause of irreversible blindness, is most effectively managed by reducing intraocular pressure (IOP). Topical eye drops, which are conventional treatments, frequently encounter constraints regarding patient compliance, inconsistent dosage, and tolerability. Slow-release drug delivery systems have emerged as a promising innovation [...] Read more.
Glaucoma, a primary cause of irreversible blindness, is most effectively managed by reducing intraocular pressure (IOP). Topical eye drops, which are conventional treatments, frequently encounter constraints regarding patient compliance, inconsistent dosage, and tolerability. Slow-release drug delivery systems have emerged as a promising innovation in response to these challenges. The objective of these systems is to enhance the efficacy of treatment and patient compliance by ensuring the consistent and sustained delivery of therapeutic agents over extended periods. Implantable devices, injectable formulations, and external applications are all categorized as slow-release therapies. By delivering medication directly to the target tissues in a controlled manner, these technologies have the potential to circumvent common issues associated with traditional regimens, such as forgotten doses or improper administration. These systems have been shown to obtain clinically meaningful reductions in IOP in studies, with some demonstrating efficacy that is comparable to that of established daily topical treatments. Despite their potential, slow-release therapies encounter obstacles that necessitate resolution. Potential complications during implantation or removal, long-term biocompatibility, and the cost of treatment are all areas of concern. Furthermore, further investigation is required to comprehensively assess their relative economic feasibility, patient acceptability, and long-term safety profiles in comparison to conventional treatments. This review summarizes the most recent findings in the scientific literature, underlining the role and possible limits of slow-release therapies in glaucoma with the aim of offering a comprehensive understanding of their potential clinical applications and challenges. This emphasizes the potential for these innovations to revolutionize care by addressing current knowledge gaps, while also emphasizing the areas in which further development and research are required. Full article
(This article belongs to the Special Issue Drug Delivery Systems for Ocular Diseases)
16 pages, 1315 KiB  
Review
Microneedles for Melanoma Therapy: Exploring Opportunities and Challenges
by Lufuno Nemakhavhani, Heidi Abrahamse and Sathish Sundar Dhilip Kumar
Pharmaceutics 2025, 17(5), 579; https://doi.org/10.3390/pharmaceutics17050579 (registering DOI) - 28 Apr 2025
Viewed by 34
Abstract
Melanoma is a type of skin cancer that originates in the melanocytes, the epidermis’ basal layer. The skin has traditionally been an attractive administration location for drug delivery in tumor therapy, and it is composed of three layers: the outermost stratum corneum (SC), [...] Read more.
Melanoma is a type of skin cancer that originates in the melanocytes, the epidermis’ basal layer. The skin has traditionally been an attractive administration location for drug delivery in tumor therapy, and it is composed of three layers: the outermost stratum corneum (SC), the middle epidermis, and the deepest layer, the dermis. Melanoma can be treated using a variety of methods, such as chemotherapy, surgery, radiotherapy, and biological therapy, but all are expensive and have side effects. Furthermore, the SC is the primary barrier that contributes to the impermeability of the skin, which is a limitation in epidermal drug transport and can aid in achieving effective drug concentration with minimal side effects at the target location. Microneedles (MNs) are tiny needles that are easy to use, inexpensive, and non-toxic. In recent years, MNs have been significantly studied for the treatment of melanoma due to their excellent biocompatibility, minimal invasion, high patient compliance, simple penetration process, and high SC penetration rate. Most notably, MNs can provide efficient and seldom unpleasant delivery carriers and synergistic effectiveness by combining multi-model techniques with immunotherapy, gene therapy, photodynamic therapy (PDT), and photothermal treatment (PTT). This review will focus on biocompatibility, biodegradability, limitations, fabrication materials, release mechanisms, and delivery of the therapeutics of MNs for melanoma treatment. Full article
(This article belongs to the Special Issue Recent Advances in Microneedle-Mediated Drug Delivery, 2nd Edition)
Show Figures

Figure 1

21 pages, 89808 KiB  
Article
Toward Natural Wound Healing Therapy: Honey and Calendula officinalis Loaded κ-Carrageenan Films with Promising Hemostatic Potential
by Jovana S. Vuković, Srđan Perišić, Anja Nikolić, Ivan Milošević, Milorad Mirilović, Bogomir Bolka Prokić and Tijana Lužajić Božinovski
Pharmaceutics 2025, 17(5), 578; https://doi.org/10.3390/pharmaceutics17050578 (registering DOI) - 28 Apr 2025
Viewed by 57
Abstract
Background/Objectives: Efficient wound treatment embraces the management of four overlapping phases, starting with hemostasis, an immediate physiological response aimed at stopping bleeding from damaged blood vessels caused by skin injury. This paper proposes an innovative, nature-based hemostatic biomaterial designed to assist natural [...] Read more.
Background/Objectives: Efficient wound treatment embraces the management of four overlapping phases, starting with hemostasis, an immediate physiological response aimed at stopping bleeding from damaged blood vessels caused by skin injury. This paper proposes an innovative, nature-based hemostatic biomaterial designed to assist natural self-healing regenerative mechanisms. Methods: Light, transparent, and skin-adhesive films based on κ-carrageenan, meadow polyfloral honey, and Calendula officinalis flower extract were fabricated via solution casting. Comprehensive characterization revealed the physicochemical, structural, swelling, and barrier properties and the influence of each bioactive compound utilized for film preparation. Results: The samples subcutaneously implanted in Wistar rats induced vascularization, deposition of collagen, and orientation of collagen fibers while being fully phagocytosed and gradually biodegraded. The rat tail-cut model demonstrated that the films significantly reduced blood loss (0.1875 ± 0.0732 g) compared to the control (0.7837 ± 0.3319 g), and hemostasis was achieved notably faster (355.75 ± 71.42 s) than in the control group (704.25 ± 85.29 s). The rat liver punch biopsy model confirmed reduced blood loss (2.8025 ± 1.5174 g) and shorter time to hemostasis (303.25 ± 77.90 s) compared to the control (3.1475 ± 1.5413 g, 383.00 ± 36.53 s). Conclusions: The results indicate the great potential of the fabricated films as hemostatic wound dressings. Full article
Show Figures

Figure 1

21 pages, 4526 KiB  
Article
Electrospun Quercetin-Loaded PLA and PLA/Polyethylene Glycol Fibers: Preparation, Characterization, and In Vitro Evaluation
by Nikoleta Stoyanova, Nasko Nachev, Ani Georgieva, Reneta Toshkova and Mariya Spasova
Pharmaceutics 2025, 17(5), 577; https://doi.org/10.3390/pharmaceutics17050577 (registering DOI) - 27 Apr 2025
Viewed by 60
Abstract
Background: The plant extract of quercetin possesses valuable pharmacological properties. However, its high instability, poor water solubility, and low cell bioavailability has limited its medical applications. An innovative approach used to overcome these limitations is the QUE incorporation in suitable polymer carriers. Methods: [...] Read more.
Background: The plant extract of quercetin possesses valuable pharmacological properties. However, its high instability, poor water solubility, and low cell bioavailability has limited its medical applications. An innovative approach used to overcome these limitations is the QUE incorporation in suitable polymer carriers. Methods: In the present study, fibrous materials based on PLA or PLA/PEG loaded with the flavonoid quercetin (QUE) were obtained by the electrospinning technique. Diverse morphological, spectroscopic, physico-mechanical, and spectrophotometric methods were used to characterize the prepared electrospun mats. Results: The addition of hydrophilic PEG to the polymer matrix improved its wettability and assisted the more rapid release of QUE from the PLA/PEG fibrous mat than from the PLA one. The obtained fibrous mats possess good mechanical properties. Moreover, QUE-loaded electrospun mats exhibited high anticancer activity against HeLa cervical cancer cells, but lower toxicity to normal cells. Conclusions: The obtained perspective results revealed the potential of the obtained QUE-loaded materials to find applications for wound healing and cancer treatment. Full article
Show Figures

Figure 1

38 pages, 3559 KiB  
Review
Nanochitin and Nanochitosan in Pharmaceutical Applications: Innovations, Applications, and Future Perspective
by José Roberto Vega-Baudrit, Mary Lopretti, Gabriela Montes de Oca, Melissa Camacho, Diego Batista, Yendry Corrales, Andrea Araya, Badr Bahloul, Yohann Corvis and Luis Castillo-Henríquez
Pharmaceutics 2025, 17(5), 576; https://doi.org/10.3390/pharmaceutics17050576 (registering DOI) - 27 Apr 2025
Viewed by 202
Abstract
Nanochitin is a nanoscale form of chitin—a polysaccharide found in the exoskeletons of crustaceans, insects, and some fungal cell walls—that is newly garnering significant attention in the pharmaceutical space. Its good properties, such as biocompatibility, biodegradability, and an easily adjustable surface, render it [...] Read more.
Nanochitin is a nanoscale form of chitin—a polysaccharide found in the exoskeletons of crustaceans, insects, and some fungal cell walls—that is newly garnering significant attention in the pharmaceutical space. Its good properties, such as biocompatibility, biodegradability, and an easily adjustable surface, render it attractive for various medical and pharmaceutical applications. Nanochitin, from drug delivery systems and wound-care formulations to vaccine adjuvants and antimicrobial strategies, has demonstrated its strong potential in meeting diverse therapeutic needs. This review covers the background of nanochitin, including methods for its extraction and refining and its principal physicochemical and biological properties. It further discusses various hydrolysis and enzymatic approaches for the structural and functional characterization of nanochitin and highlights some pharmaceutical applications where this biopolymer has been studied. The review also addresses toxicity issues, regulatory matters, and challenges in large-scale industrial production. Finally, it underscores novel avenues of investigation and future opportunities, emphasizing the urgent requirement for standardized production methods, rigorous safety assessment, and interdisciplinary partnerships to maximize nanochitin’s potential in pharmaceutical research, demonstrating the importance of chitin in drug delivery. Full article
(This article belongs to the Section Nanomedicine and Nanotechnology)
Show Figures

Figure 1

14 pages, 5530 KiB  
Article
Intranasal Application of Foxp3 Introduced with Poly(d,l-lactic-co-glycolic acid) (PLGA) Nanoparticles (Foxp3 NPs) Attenuates Allergic Inflammation in a Mouse Model of Allergic Rhinitis
by Seung Cheol Han, Sunhee Yeon, Hyejeen Kim and Sookyoung Park
Pharmaceutics 2025, 17(5), 575; https://doi.org/10.3390/pharmaceutics17050575 (registering DOI) - 27 Apr 2025
Viewed by 95
Abstract
Background: Allergic rhinitis (AR) is a common disease that requires more convenient, safe, and effective therapy. This study aimed to investigate the therapeutic effect of Forkhead box protein3 (Foxp3) introduced with poly(d,l-lactic-co-glycolic acid) (PLGA) nanoparticles (Foxp3 NPs) in [...] Read more.
Background: Allergic rhinitis (AR) is a common disease that requires more convenient, safe, and effective therapy. This study aimed to investigate the therapeutic effect of Forkhead box protein3 (Foxp3) introduced with poly(d,l-lactic-co-glycolic acid) (PLGA) nanoparticles (Foxp3 NPs) in an AR mouse model. Methods: A murine model of allergic rhinitis was established using BALB/c mice through initial sensitization by intraperitoneal administration of ovalbumin (OVA), followed by repeated intranasal OVA challenges. Foxp3 plasmid-loaded PLGA nanoparticles were subsequently administered via either the intranasal or intraperitoneal route to evaluate therapeutic efficacy. Episodes of sneezing and nose rubbing were counted. The serum total IgE, OVA-specific IgE, and cytokine levels in nasal lavage fluid (NALF) were determined by ELISA (Enzyme-Linked ImmunoSorbent Assay). Nasal mucosa from each group were analyzed using protein, reverse transcriptase–polymerase chain reaction (RT-PCR), and histological analyses. Result: Rubbing and sneezing symptoms improved in the Foxp3 NPs intranasal administration group. Foxp3 NPs intranasal administration markedly ameliorated OVA-induced nasal allergic inflammation. The total IgE and OVA-specific IgE serum level and IL-4, IL-13 expression levels of NALF were significantly decreased in the treated Foxp3 NPs group. The histopathological results of nasal mucosa were also normal, with no cellular infiltration and no inflammation in the Foxp3 NPs group. Conclusions: These results suggest that Foxp3 NPs alleviate nasal allergic inflammation and may have therapeutic value in the treatment of AR. Full article
(This article belongs to the Section Nanomedicine and Nanotechnology)
Show Figures

Figure 1

17 pages, 4078 KiB  
Article
Hydrophobic Ion Pairing of Polymyxin B with Oleic Acid: A Dissipative Particle Dynamics Simulation Study
by Nargess Mehdipour, Sima Kiani and Hossein Eslami
Pharmaceutics 2025, 17(5), 574; https://doi.org/10.3390/pharmaceutics17050574 (registering DOI) - 27 Apr 2025
Viewed by 101
Abstract
Background: Hydrophobic ion pairing is a technique for reducing the hydrophilicity of charged molecules (drugs) by pairing them with oppositely charged hydrophobic counterions. This method is used to control the solubility of charged molecules in a solvent and is of particular importance in [...] Read more.
Background: Hydrophobic ion pairing is a technique for reducing the hydrophilicity of charged molecules (drugs) by pairing them with oppositely charged hydrophobic counterions. This method is used to control the solubility of charged molecules in a solvent and is of particular importance in drug delivery. Methods: Dissipative particle dynamics simulations were performed to provide a microscopic understanding of hydrophobic ion pairing in polymyxin B (PMB) and oleate (OA) ions. Solvents and ions were explicitly included in the simulations. Results: We investigated the effects of relative concentrations of PMB and OA (the charge ratio), solvent philicity, and the concentrations of PMB and OA at a fixed composition on the structural stability and the hydrophobicity of the ion paired cluster, as well as the kinetics of assembly. The maximum hydrophobicity belongs to PMB:OA charge ratio 1:1. The clustering efficiency in mixed ethanol–water solutions decreases with the increasing ethanol content of water. The dynamics of PMB/OA exchange between hydrophobic cluster and the surrounding solution reveal two distinct relaxation processes, whose relaxation times differ by two orders of magnitude. Conclusions: The hydrophobicity of the cluster is controlled by the charge ratio. The core of the ion paired cluster acts as the primary barrier and its surface layer acts as the secondary barrier against alcohol permeation into it. The exchange of surface PMB/OA ions with the surrounding is a much faster dynamic process than the establishment of equilibrium between the PMB/OA ions in the cluster and the solution. The time scale for the slower process provides useful information on the rate of drug release from the hydrophobic ion paired complex. Full article
(This article belongs to the Section Physical Pharmacy and Formulation)
Show Figures

Graphical abstract

22 pages, 25653 KiB  
Article
Synergistic Antioxidant and Anti-Ferroptosis Therapy via BPNS-Encapsulated Thermoresponsive Chitosan Hydrogel for Spinal Cord Injury Regeneration
by Yang Liu, Yingkai Wang, Xiangzi Wang, Wanchen Zeng, Zehong Zhang, Zhengmian Zhang and Zhongquan Qi
Pharmaceutics 2025, 17(5), 573; https://doi.org/10.3390/pharmaceutics17050573 (registering DOI) - 26 Apr 2025
Viewed by 181
Abstract
Background: Spinal cord injury (SCI) is a devastating neurological condition with limited therapeutic options. Current clinical interventions predominantly rely on prolonged or high-dose pharmacological regimens, often causing systemic toxicity and adverse events. Although black phosphorus nanosheets (BPNSs) exhibit remarkable reactive oxygen species [...] Read more.
Background: Spinal cord injury (SCI) is a devastating neurological condition with limited therapeutic options. Current clinical interventions predominantly rely on prolonged or high-dose pharmacological regimens, often causing systemic toxicity and adverse events. Although black phosphorus nanosheets (BPNSs) exhibit remarkable reactive oxygen species (ROS)-scavenging capacity to mitigate oxidative damage, their rapid degradation severely compromises their therapeutic efficacy. Methods: This study presents a thermosensitive hydrogel with rapid gelation properties by incorporating different proportions and concentrations of sodium alginate (SA) into a chitosan/β-glycerophosphate (CS/β-GP) hydrogel and loading it with BPNS for the treatment of SCI in rats. In vitro, the physical properties of the composite were characterized and the cytotoxicity and ROS scavenging abilities were assessed using PC12 cells; in vivo, behavioral tests, histopathological analysis, transcriptomics, immunohistochemistry, and Western blotting were performed to explore the therapeutic effects and mechanisms. Results: The results demonstrate that this hydrogel effectively slows BPNS degradation, exhibits a high ROS scavenging capacity, reduces lipid peroxidation, and thereby inhibits ferroptosis and apoptosis, offering neuroprotective effects and promoting motor function recovery. Conclusions: Our findings establish the CS/β-GP/SA-BPNS hydrogel as a multifunctional therapeutic platform for SCI, synergizing sustained drug release with ROS–ferroptosis–apoptosis axis modulation to achieve neuroprotection and functional restoration. This strategy provides a translatable paradigm for combining nanotechnology and biomaterial engineering in neural repair. Full article
(This article belongs to the Section Nanomedicine and Nanotechnology)
Show Figures

Figure 1

18 pages, 4841 KiB  
Article
Combination Therapy for Overcoming Multidrug Resistance in Breast Cancer Through Hedgehog Signaling Pathway Regulation
by Yujie Liu, Yiliang Yang and Xianrong Qi
Pharmaceutics 2025, 17(5), 572; https://doi.org/10.3390/pharmaceutics17050572 (registering DOI) - 26 Apr 2025
Viewed by 82
Abstract
Background/Objectives: The ineffective delivery of drugs into tumors and the existence of multidrug resistance (MDR) are the primary causes of chemotherapy failure. Downregulation of the Sonic Hedgehog (Shh) pathway has been shown to reduce P-glycoprotein (P-gp) expression on cell membranes and to resist [...] Read more.
Background/Objectives: The ineffective delivery of drugs into tumors and the existence of multidrug resistance (MDR) are the primary causes of chemotherapy failure. Downregulation of the Sonic Hedgehog (Shh) pathway has been shown to reduce P-glycoprotein (P-gp) expression on cell membranes and to resist MDR. Methods: In this study, we combine cyclopamine (CYP, a potent Shh antagonist) with paclitaxel (PTX, an antitumor drug that can produce MDR) in a nano-drug delivery system (CYP NP and PTX NP) for the treatment of drug-resistant breast cancer. Nanoparticles were characterized for size, zeta potential, and encapsulation efficiency. P-gp expression, nanoparticle accumulation, cytotoxicity, and apoptosis were evaluated in MCF-7 and MCF-7/Adr cells. Penetration ability was assessed using 3D multicellular tumor spheroids. Antitumor efficacy and nanoparticle biodistribution were validated in MCF-7/Adr-bearing nude mice models. Results: Our engineered CYP nanoparticles (~200 nm) demonstrated prolonged intratumoral retention, enabling sustained Shh pathway inhibition and P-gp functional suppression. This size-optimized formulation created a favorable tumor microenvironment for the smaller PTX nanoparticles (~30 nm), facilitating deeper tumor penetration and enhanced cellular uptake. Meanwhile, by down-regulating P-gp expression, CYP NPs could convert drug-resistant cells to PTX-sensitive cells in both cytotoxicity and apoptosis induction through the Shh pathway. The combination of CYP NP and PTX NP augmented the antitumor effects in MCF-7/Adr-bearing nude mice models. Conclusions: The CYP NP and PTX NP combination offers a new therapeutic strategy in cancer treatment. Full article
(This article belongs to the Special Issue Nanotechnology Advances for Breast Cancer Treatment)
Show Figures

Graphical abstract

14 pages, 2415 KiB  
Article
Influence of Ionization and the Addition of Cyclodextrins and Hydrophilic Excipients on the Solubility of Benzthiazide, Isoxicam, and Piroxicam
by Diego Lucero-Borja, Rebeca Ruiz, Elisabet Fuguet and Clara Ràfols
Pharmaceutics 2025, 17(5), 571; https://doi.org/10.3390/pharmaceutics17050571 (registering DOI) - 25 Apr 2025
Viewed by 93
Abstract
Background: The bioavailability of a drug depends, among other parameters, on solubility. One of the strategies used to enhance the solubility of sparingly soluble drugs is the use of excipients. Excipients can interact with the drug by increasing its solubility and/or stabilizing [...] Read more.
Background: The bioavailability of a drug depends, among other parameters, on solubility. One of the strategies used to enhance the solubility of sparingly soluble drugs is the use of excipients. Excipients can interact with the drug by increasing its solubility and/or stabilizing supersaturated solutions. Some of the most common excipients are cyclodextrins and hydrophilic polymers. Objectives: The effect of two cyclodextrins (captisol and cavasol) and three hydrophilic polymers (klucel, kollidon and plasdone S630) on the solubility of three ionizable drugs (benzthiazide, isoxicam, and piroxicam) is evaluated at biorelevant pH values, using two complementary techniques. Methods: The solubility enhancement was evaluated by the comparison of the solubility with and without the presence of excipients through the shake-flask and CheqSol methodology. Results: Captisol and cavasol slightly increase the concentration of the neutral species of the drugs in the solution before precipitation begins, although they do not enhance the supersaturation duration nor the thermodynamic solubility of the drugs. The increase in solubility in the presence of cyclodextrins is mainly caused by the ionization state of the drug. Hydrophilic polymers not only improve thermodynamic solubility but also the extent and the duration of the supersaturation. Some metastable forms are observed for benzthiazide and isoxicam in the presence of kollidon and plasdone S630. Conclusions: The shake-flask method enabled the evaluation of thermodynamic solubility both in the absence and presence of excipients. Meanwhile, the CheqSol method provided insights into the presence of supersaturated solutions. Different behavior is observed depending on the nature of the excipient. Full article
Show Figures

Figure 1

18 pages, 2736 KiB  
Article
Intrinsic Dissolution Modeling: Interdependence Between Dissolution Rate, Solubility, and Boundary Layer Thickness
by Amelie Marie Mattusch, Gerhard Schaldach, Jens Bartsch and Markus Thommes
Pharmaceutics 2025, 17(5), 570; https://doi.org/10.3390/pharmaceutics17050570 - 25 Apr 2025
Viewed by 85
Abstract
Background/Objectives: In the past, many drug release models have been presented which attempt to describe the interaction of drugs and excipients in a formulation. Nevertheless, modeling the intrinsic dissolution behavior is essential for understanding the fundamental dissolution mechanisms of drugs and for [...] Read more.
Background/Objectives: In the past, many drug release models have been presented which attempt to describe the interaction of drugs and excipients in a formulation. Nevertheless, modeling the intrinsic dissolution behavior is essential for understanding the fundamental dissolution mechanisms of drugs and for enhancing the quality of computational approaches in the long term. Methods: In this study, the intrinsic dissolution of various pharmaceutical model substances (benzocaine, carbamazepine, griseofulvin, ibuprofen, naproxen, phenytoin, theophylline monohydrate, and trimethoprim) was investigated in dissolution experiments, taking into account the flow conditions in a dissolution channel apparatus. A practicable and generally valid representation was identified to describe the diffusion properties of the drugs in terms of the boundary layer thickness without considering the particle size distribution, physical state, or viscoelastic properties. This representation was supported by numerical simulations using a high-resolution mesh. The influence of the topography on the modeling was also examined. Results: Besides the prediction of the influence of a surface reaction limitation or the solubility of a diffusion controlled drug, the boundary layer thickness at the tablet surface is modellable in terms of a freely selectable length and as a function of the diffusion coefficient, drug solubility, and the flow velocity of the dissolution medium. Conclusions: Using different methods and a large dataset, this study presents a modeling approach that can contribute to a deeper understanding of intrinsic dissolution behavior. Full article
Show Figures

Graphical abstract

22 pages, 12952 KiB  
Article
Ionotropic Gelation and Chemical Crosslinking as Tools to Obtain Gellan Gum-Based Beads with Mesalazine
by Piotr Gadziński, Agnieszka Skotnicka, Natalia Lisiak, Ewa Totoń, Błażej Rubiś, Ewa Florek, Dariusz T. Mlynarczyk, Mirosław Szybowicz, Ewelina Nowak and Tomasz Osmałek
Pharmaceutics 2025, 17(5), 569; https://doi.org/10.3390/pharmaceutics17050569 (registering DOI) - 25 Apr 2025
Viewed by 235
Abstract
Introduction: Many orally administered drugs are either unstable in the acidic environment of the stomach or cause moderate to severe side effects in the upper gastrointestinal tract (GIT). These limitations can reduce therapeutic efficacy, discourage patient compliance, worsen the disease, and even contribute [...] Read more.
Introduction: Many orally administered drugs are either unstable in the acidic environment of the stomach or cause moderate to severe side effects in the upper gastrointestinal tract (GIT). These limitations can reduce therapeutic efficacy, discourage patient compliance, worsen the disease, and even contribute to the risk of cancer development. To overcome these issues, drug release often needs to be modified and targeted to the distal parts of the GIT. This is typically achieved through the use of pH-sensitive polymer coatings or incorporation into polymeric delivery systems. With this in mind, the aim of this project was to design, develop, and characterize gellan gum-based beads for colon-specific prolonged release of mesalazine, with potential application in the chemoprevention and treatment of bowel diseases. Materials and Methods: The dehydrated capsules were characterized using Raman spectroscopy and scanning electron microscopy. The crosslinked gellan gum was additionally evaluated for cytotoxicity. Key parameters such as pH-dependent swelling behavior, drug content, encapsulation efficiency, and drug release in simulated gastrointestinal fluids were also assessed. Furthermore, the behavior of the capsules in the gastrointestinal tract was studied in a rat model to evaluate their in vivo performance. Results: Significant differences in drug release profiles were observed between formulations crosslinked solely with calcium ions and those additionally crosslinked with glutaraldehyde (GA). The incorporation of GA effectively prolonged the release of mesalazine. These findings were further supported by in vivo studies conducted on Wistar rats, where the GA-crosslinked formulation demonstrated a markedly extended release compared to the formulation prepared using only ionotropic gelation. Conclusions: The combination of ionotropic gelation and glutaraldehyde crosslinking in gellan gum-based beads appears to be a promising strategy for achieving colon-specific prolonged release of mesalazine, facilitating targeted delivery to the distal regions of the gastrointestinal tract. Full article
Show Figures

Figure 1

24 pages, 15011 KiB  
Article
Process Development for the Continuous Manufacturing of Carbamazepine-Nicotinamide Co-Crystals Utilizing Hot-Melt Extrusion Technology
by Lianghao Huang, Wen Ni, Yaru Jia, Minqing Zhu, Tiantian Yang, Mingchao Yu and Jiaxiang Zhang
Pharmaceutics 2025, 17(5), 568; https://doi.org/10.3390/pharmaceutics17050568 - 25 Apr 2025
Viewed by 159
Abstract
Objectives: Hot-melt extrusion (HME) offers a solvent-free, scalable approach for manufacturing pharmaceutical co-crystals (CCs), aligning with the industry’s shift to continuous manufacturing (CM). However, challenges like undefined yield optimization, insufficient risk management, and limited process analytical technology (PAT) integration hinder its industrial application. [...] Read more.
Objectives: Hot-melt extrusion (HME) offers a solvent-free, scalable approach for manufacturing pharmaceutical co-crystals (CCs), aligning with the industry’s shift to continuous manufacturing (CM). However, challenges like undefined yield optimization, insufficient risk management, and limited process analytical technology (PAT) integration hinder its industrial application. This study aimed to develop a proof-of-concept HME platform for CCs, assess process risks, and evaluate PAT-enabled monitoring to facilitate robust production. Methods: Using carbamazepine (CBZ) and nicotinamide (NIC) as model compounds, an HME platform compatible with PAT tools was established. A systematic risk assessment identified five key risk domains: materials, machinery, measurement, methods, and other factors. A Box–Behnken design of experiments (DoE) evaluated the impact of screw speed, temperature, and mixing sections on CC quality. Near-infrared (NIR) spectroscopy monitored CBZ-NIC co-crystal formation in real time during HME process. Results: DoE revealed temperature and number of mixing sections significantly influenced particle size (D50: 2.0–4.0 μm), while screw speed affected efficiency. NIR spectroscopy detected a unique CC absorption peak at 5008.3 cm⁻¹, enabling real-time structural monitoring with high accuracy (R² = 0.9999). Risk assessment highlighted material attributes, process parameters, and equipment design as critical factors affecting CC formation. All experimental batches yielded ≥ 94% pure CCs with no residual starting materials, demonstrating process reproducibility and robustness. Conclusions: Overall, this work successfully established a continuous hot-melt extrusion (HME) process for manufacturing CBZ-NIC co-crystals, offering critical insights into material, equipment, and process parameters while implementing robust in-line NIR monitoring for real-time quality control. Additionally, this work provides interpretable insights and serves as a basis for future machine learning (ML)-driven studies. Full article
(This article belongs to the Special Issue Advances in Hot Melt Extrusion Technology)
Show Figures

Figure 1

20 pages, 2208 KiB  
Article
Food Effect and Formulation: How Soluble Fillers Affect the Disintegration and Dissolution of Tablets in Viscous Simulated Fed State Media
by Muhammad Farooq Umer, Valentin Stahl, Jozef Al-Gousous, Thomas Nawroth, Wei-Jhe Sun, Fang Wu, Wenlei Jiang, Zongming Gao and Peter Langguth
Pharmaceutics 2025, 17(5), 567; https://doi.org/10.3390/pharmaceutics17050567 - 25 Apr 2025
Viewed by 192
Abstract
The food-induced viscosity of the media can alter tablet disintegration and eventually the release of the drug it contains. The extent of this retardation depends on tablet formulation factors, such as the solubility of its excipients. Objectives: This research aimed to study [...] Read more.
The food-induced viscosity of the media can alter tablet disintegration and eventually the release of the drug it contains. The extent of this retardation depends on tablet formulation factors, such as the solubility of its excipients. Objectives: This research aimed to study the effect of filler solubility on the disintegration and dissolution of tablets under different testing conditions. Methods: Tablet formulations containing acetaminophen (as a model compound), mixtures of different ratios of fillers, and other excipients were directly compressed using uniform manufacturing parameters. These formulations were investigated under fasted- and fed-state conditions to determine the influence of viscosity on their disintegration, inspired by the liquid penetration ratio (LPR) theoretical framework. Disintegration and dissolution tests were performed using both compendial and novel testing apparatuses. Results: The soluble fillers in the tablets affected their disintegration and dissolution in the simulated fed-state medium, while fasted-state conditions affected the tablets only marginally. The testing devices showed partially contrasting results, which appeared to be due to the hydrodynamics of the testing media used. The novel CNC (computed numerical control) apparatus offered 3D motion and effectively exposed the tablets to the viscous testing media, unlike the compendial paddle apparatus. Conclusions: This study explored the impact of filler solubility on the disintegration and dissolution of tablets. As the LPR framework revealed, fillers with a higher solubility have positive effects on the disintegration and dissolution of tablets in viscous conditions. Additionally, the proportion of soluble filler used is also inversely correlated with the disintegration time. Further investigation of the formulation parameters, as well as the testing conditions, would provide additional insights into the effects of food on these tablets. Full article
Show Figures

Graphical abstract

21 pages, 7502 KiB  
Article
Low-Cost Microfluidic Mixers: Are They up to the Task?
by Jade Forrester, Callum G. Davidson, May Blair, Lynn Donlon, Daragh M. McLoughlin, Chukwuebuka R. Obiora, Heather Stockdale, Ben Thomas, Martina Nutman, Sarah Brockbank, Zahra Rattray and Yvonne Perrie
Pharmaceutics 2025, 17(5), 566; https://doi.org/10.3390/pharmaceutics17050566 - 25 Apr 2025
Viewed by 272
Abstract
Background/Objectives: Microfluidic mixing has become the gold standard procedure for manufacturing nucleic acid lipid-based delivery systems, offering precise control over critical process parameters. The choice and design of microfluidic mixers are often seen as a key driving force affecting the critical quality [...] Read more.
Background/Objectives: Microfluidic mixing has become the gold standard procedure for manufacturing nucleic acid lipid-based delivery systems, offering precise control over critical process parameters. The choice and design of microfluidic mixers are often seen as a key driving force affecting the critical quality attributes of the resulting lipid nanoparticles (LNPs). Methods: This study aimed to evaluate LNPs manufactured using two low-cost microfluidic mixers alongside manual mixing (pipette mixing (PM)), followed by characterization studies using orthogonal analytics as well as expression studies to establish whether low-cost microfluidic manufacturing methods are suitable for bench-scale and high-throughput research. Results: The results show that all manufacturing methods can produce LNPs with sizes ranging between 95 and 215 nm with high encapsulation (70–100%), and enhanced analytics showed variations between the LNPs produced using the different mixers. Despite these differences, pipette mixing production of LNPs demonstrated its application as a high-throughput screening tool for LNPs, effectively distinguishing between different formulations and predicting consistent expression patterns both in vitro and in vivo. Conclusions: Overall, these results validate the use of low-cost microfluidic mixers without compromising the efficiency and integrity of the resulting LNPs. This study supports the increased accessibility of small-scale LNP manufacturing and high-throughput screening. Full article
(This article belongs to the Section Nanomedicine and Nanotechnology)
Show Figures

Graphical abstract

16 pages, 2855 KiB  
Article
Optimization of a Newly Developed Chamber Setup for Spatial Dust Measurements in the Context of Containment
by Hendrik Küllmar, Martin Schöler and Claudia S. Leopold
Pharmaceutics 2025, 17(5), 565; https://doi.org/10.3390/pharmaceutics17050565 - 25 Apr 2025
Viewed by 217
Abstract
Background/Objectives: A specially designed chamber setup for containment investigations of pharmaceutical dusts was recently developed. The aim of the present study was to optimize the measurement procedure with this chamber setup, focusing on the atomization parameters. The optimization was aimed at a maximization [...] Read more.
Background/Objectives: A specially designed chamber setup for containment investigations of pharmaceutical dusts was recently developed. The aim of the present study was to optimize the measurement procedure with this chamber setup, focusing on the atomization parameters. The optimization was aimed at a maximization of the amount of detected dust and a minimization of the required sample mass. Methods: For this purpose, the safe surrogate substance acetaminophen was used for dust measurements. In addition to the atomization parameters investigated by a design of experiments, the cleaning of the chamber setup and the selection of two different types of acetaminophen with different physicochemical properties were examined. Results: By altering the cleaning method of the chamber setup, more than a tenfold increase of detected acetaminophen was observed. In addition, by selecting the more appropriate acetaminophen type, the totally detected acetaminophen amount was further increased by more than 25%. By means of the design of experiments two models were developed, one dealing with the atomization parameters with regard to the atomization effectiveness and the other describing their influence on the spatial dust distribution of acetaminophen. Based on the model for atomization effectiveness, the totally detected acetaminophen amount may be increased by more than double at a constant sample mass. Conclusions: In summary, the measurement procedure of the chamber setup was optimized in terms of the cleaning method, surrogate choice, and the adjustment of the atomization parameters, giving valuable insights to deepen our understanding of dustiness and the spatial distribution of dust in the context of containment. Full article
(This article belongs to the Section Pharmaceutical Technology, Manufacturing and Devices)
Show Figures

Graphical abstract

3 pages, 697 KiB  
Correction
Correction: van den Born-Bondt et al. Development of an Adaptable Qualification Test Set for Personnel Involved in Visual Inspection Procedures of Parenteral Drug Products Manufactured Under Good Manufacturing Practice Conditions in Hospital Pharmacy Compounding Facilities. Pharmaceutics 2025, 17, 74
by Tessa van den Born-Bondt, Harmen P. S. Huizinga, Koen R. Kappert, Hans H. Westra, Jacoba van Zanten, Herman J. Woerdenbag, Jacoba M. Maurer and Bahez Gareb
Pharmaceutics 2025, 17(5), 564; https://doi.org/10.3390/pharmaceutics17050564 - 25 Apr 2025
Viewed by 74
Abstract
In the original publication [...] Full article
Show Figures

Figure 4

13 pages, 2007 KiB  
Article
Membrane-Mediated Action of Phosphodiesterase 5 Inhibitors
by Anna I. Malykhina, Svetlana S. Efimova and Olga S. Ostroumova
Pharmaceutics 2025, 17(5), 563; https://doi.org/10.3390/pharmaceutics17050563 - 24 Apr 2025
Viewed by 113
Abstract
Background/Objectives: Phosphodiesterase 5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, activate the cyclic guanosine monophosphate pathway resulting in vascular smooth muscle relaxation. They have been tested for a broad variety of conditions from cancer to Alzheimer’s disease with a positive impact. The known [...] Read more.
Background/Objectives: Phosphodiesterase 5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, activate the cyclic guanosine monophosphate pathway resulting in vascular smooth muscle relaxation. They have been tested for a broad variety of conditions from cancer to Alzheimer’s disease with a positive impact. The known mechanism of action of these drugs could not explain such a plethora of effects. We studied the influence of PDE5 inhibitors on lipid bilayers as a possible application point of their action. Methods: To monitor the membrane changes induced by PDE5 inhibitors, the differential scanning microcalorimetry and the molecular dynamics simulation were used. Results: We found that sildenafil, vardenafil, and tadalafil change elastic properties of model membranes: PDE5 inhibitors disorder thin membranes and order thick membranes. Moreover, PDE inhibitors were able to induce lipid interdigitation. To address the biological aspect of the findings, we performed molecular dynamics on smooth muscle cell’s lipid raft treated with PDE5 inhibitors and revealed the increased density of the lipids. Furthermore, we showed that the lipid condensation in the PDE inhibitors presence increases nitric oxide permeability. Conclusions: The obtained results may be of biological relevance as lipid raft thickening might have an impact on membrane protein function. Moreover, improved nitric oxide flow through membrane may partially explain therapeutic action of these drugs. The presented results are useful for finding novel implications for PDE inhibitors. Full article
(This article belongs to the Special Issue Recent Advances in Inhibitors for Targeted Therapies)
Show Figures

Figure 1

23 pages, 4258 KiB  
Article
Box-Behnken Design Assisted Optimization and Characterization of Chitosan Film for Simultaneous Topical Delivery of Ascorbic Acid and Metronidazole
by Bilawal Khan, Pakorn Kraisit, Supaporn Santhan and Namon Hirun
Pharmaceutics 2025, 17(5), 562; https://doi.org/10.3390/pharmaceutics17050562 (registering DOI) - 24 Apr 2025
Viewed by 200
Abstract
Background/Objectives: The objective of this study was to develop chitosan films plasticized with glycerol for the topical delivery of ascorbic acid and metronidazole. Methods: The films were prepared using a casting technique in which an aqueous ascorbic acid solution served as the solvent, [...] Read more.
Background/Objectives: The objective of this study was to develop chitosan films plasticized with glycerol for the topical delivery of ascorbic acid and metronidazole. Methods: The films were prepared using a casting technique in which an aqueous ascorbic acid solution served as the solvent, eliminating the need for additional mineral or organic acids. The influence of compositions on film characteristics—specifically mechanical properties and surface pH—was examined, and an optimized formulation was identified using a Box-Behnken design-response surface methodology. Relevant characterization techniques and in vitro evaluations were conducted to assess the properties and performance of the optimized film formulation. Results: Results showed that both glycerol and ascorbic acid contributed to the plasticization of the films. Fourier-transform infrared spectroscopic analysis of the optimized film revealed the formation of chitosan ascorbate and interactions between chitosan and glycerol. In addition, the thermogram and powder X-ray diffractogram demonstrated alterations in the thermal behavior and crystallinity of the embedded bioactive compounds. The developed film possessed the preferred swelling capacity. Moreover, in vitro release studies revealed a co-release pattern, delivering both bioactive compounds simultaneously. Conclusions: These findings suggest that the prepared chitosan-based film could serve as a promising platform for topical delivery. Full article
(This article belongs to the Special Issue Carbohydrate-Based Carriers for Drug Delivery, 2nd Edition)
Show Figures

Figure 1

24 pages, 3847 KiB  
Article
Silver Nanoparticles with Mebeverine in IBS Treatment: DFT Analysis, Spasmolytic, and Anti-Inflammatory Effects
by Mihaela Stoyanova, Miglena Milusheva, Vera Gledacheva, Mina Todorova, Nikoleta Kircheva, Silvia Angelova, Iliyana Stefanova, Mina Pencheva, Bela Vasileva, Kamelia Hristova-Panusheva, Natalia Krasteva, George Miloshev, Yulian Tumbarski, Milena Georgieva and Stoyanka Nikolova
Pharmaceutics 2025, 17(5), 561; https://doi.org/10.3390/pharmaceutics17050561 - 24 Apr 2025
Viewed by 208
Abstract
Background/Objectives: Mebeverine hydrochloride (MBH) is an antispasmodic agent used to regulate bowel movements and relax intestinal smooth muscle, but its application is limited by specific side effects; therefore, this study investigates the effects of previously synthesized MBH-loaded silver nanoparticles (AgNPs) on smooth [...] Read more.
Background/Objectives: Mebeverine hydrochloride (MBH) is an antispasmodic agent used to regulate bowel movements and relax intestinal smooth muscle, but its application is limited by specific side effects; therefore, this study investigates the effects of previously synthesized MBH-loaded silver nanoparticles (AgNPs) on smooth muscle contractile activity and their anti-inflammatory potential as an alternative delivery system. Methods: The interactions of AgNPs with cholinergic inhibitors, selective antagonists, Ca2+ blockers, and key neurotransmitters were analyzed. In vitro, albumin denaturation suppression and ex vivo assays evaluated the anti-inflammatory effects of AgNPs-MBH, validated using a DFT in silico approach. To comprehensively assess the systemic impact and IBS treatment potential of AgNPs-MBH, we also examined in vitro their antimicrobial activity and hepatic cell responses, as the liver is a key organ in evaluating the overall safety and efficacy of nanoparticles. Additionally, the drug-release capabilities of Ag NPs were established. Results: Our findings indicate that AgNPs with MBH do not affect blocked cholinergic receptors, but their effects are more pronounced and distinct in amplitude and character than MBH. MBH-loaded AgNPs showed a lower anti-inflammatory effect than MBH but were still better than diclofenac. They also affected hepatic cell morphology and proliferation, suggesting potential for enhanced therapeutic efficacy. Drug-loaded AgNPs are considered not bactericidal. Conclusions: Based on our results, drug-loaded AgNPs might be a promising medication delivery system for MBH and a useful treatment option for IBS. Future in vivo and preclinical experiments will contribute to the establishment of drug-loaded AgNPs in IBS treatment. Full article
Show Figures

Figure 1

11 pages, 9036 KiB  
Article
Physiologically Based Pharmacokinetic Modeling of Biologic Case Studies in Monkeys and Humans Reveals the Necessity of an Additional Clearance Term
by Felix Stader, Pradeep Sharma, Weize Huang, Mary P. Choules, Marie-Emilie Willemin, Xinwen Zhang, Estelle Yau, Abdallah Derbalah, Adriana Zyla, Cong Liu and Armin Sepp
Pharmaceutics 2025, 17(5), 560; https://doi.org/10.3390/pharmaceutics17050560 - 24 Apr 2025
Viewed by 226
Abstract
Background/Objectives: Physiologically based pharmacokinetic (PBPK) modeling is an important tool in biologic drug development. However, a standardized modeling strategy is currently missing. A cross-industry collaboration developed PBPK models for seven case studies, including monoclonal antibodies, antibody–drug conjugates, and bispecific T-cell engagers, to [...] Read more.
Background/Objectives: Physiologically based pharmacokinetic (PBPK) modeling is an important tool in biologic drug development. However, a standardized modeling strategy is currently missing. A cross-industry collaboration developed PBPK models for seven case studies, including monoclonal antibodies, antibody–drug conjugates, and bispecific T-cell engagers, to identify key parameters and establish a workflow to simulate biologic drugs in monkeys and in humans. Methods: PBPK models were developed in the monkey with limited data, including the molecular weight, the binding affinity to FcRn, and the additional systemic clearance of IgG, which is 20% of the total clearance. The binding affinity was only available for human FcRn and corrected for the known species-dependent differences in IgG binding. The strategy of monkey simulations was evaluated with an additional 14 studies published in the literature. Three different scenarios were simulated in humans afterwards: without, with allometrically scaled, and with optimized additional systemic clearance. Results: The plasma peak concentration and the area under the curve were predicted within 50% of the observed data for all studied case examples in the monkey, which demonstrates that sparse input parameters are sufficient for successful predictions in the monkey. Simulations in humans demonstrated the need for additional systemic clearance, because drug exposure was highly overpredicted without an additional systemic clearance term. Allometric scaling improved the predictions, but optimization led to the best fit, which is currently a limitation in the translation from animals to humans. Conclusions: This work highlights the importance of understanding the general mechanisms of drug uptake in different tissue types and cells in both target-dependent and -independent processes. Full article
Show Figures

Figure 1

24 pages, 1250 KiB  
Review
Breaking the Resistance: Photodynamic Therapy in Cancer Stem Cell-Driven Tumorigenesis
by Sheeja S. Rajan, J. P. Jose Merlin and Heidi Abrahamse
Pharmaceutics 2025, 17(5), 559; https://doi.org/10.3390/pharmaceutics17050559 - 24 Apr 2025
Viewed by 213
Abstract
Cancer stem cells (CSCs) are essential for the growth of malignancies because they encourage resistance to cancer therapy and make metastasis and relapse easier. To effectively tackle the obstacles presented by CSCs, novel therapeutic approaches are required. Photodynamic therapy (PDT) is a promising [...] Read more.
Cancer stem cells (CSCs) are essential for the growth of malignancies because they encourage resistance to cancer therapy and make metastasis and relapse easier. To effectively tackle the obstacles presented by CSCs, novel therapeutic approaches are required. Photodynamic therapy (PDT) is a promising treatment option for cancer cells, which uses light-sensitive medications that are activated by light wavelengths. This review investigates the use of PDT to overcome malignancies driven by CSCs that have innate resistance mechanisms. PDT works by causing tumor cells to accumulate photosensitizers (PSs) selectively. The reactive oxygen species (ROS), which kill cells, are released by these PSs when they are stimulated by light. According to recent developments in PDT, its efficacy may go beyond traditional tumor cells, providing a viable remedy for the resistance shown by CSCs. Researchers want to improve the targeted elimination and selective targeting of CSCs by combining PDT with new PSs and customized delivery systems. Studies emphasize how PDT affects CSCs as well as bulk tumor cells. According to studies, PDT not only limits CSC growth but also modifies their microenvironment, which lowers the possibility of recovery. Additionally, studies are being conducted on the utilization of PDT and immunotherapeutic techniques to improve treatment efficacy and overcome inherent resistance of CSCs. In conclusion, PDT is a viable strategy for treating carcinogenesis driven by CSCs. By applying the most recent advancements in PDT technologies and recognizing how it interacts with CSCs, this treatment has the potential to surpass traditional resistance mechanisms and improve the future of cancer patients. Clinical and preclinical studies highlight that combining PDT with CSC-targeted approaches has the potential to overcome current therapy limitations. Future efforts should focus on clinical validation, optimizing light delivery and PS use, and developing effective combination strategies to target CSCs. Full article
Show Figures

Figure 1

28 pages, 626 KiB  
Review
Metformin-Based Combination Approaches for Triple-Negative Breast Cancer
by Zaid Sirhan, Aya Abu Nada, Nadeen Anabtawi, Anita Thyagarajan and Ravi P. Sahu
Pharmaceutics 2025, 17(5), 558; https://doi.org/10.3390/pharmaceutics17050558 - 24 Apr 2025
Viewed by 194
Abstract
Numerous anti-diabetic medications, including metformin, have been explored for their anticancer effects because of the substantial correlation between diabetes and cancer incidence. Metformin has recently gained interest for its anticancer effects against malignancies such as breast cancer, one of the leading causes of [...] Read more.
Numerous anti-diabetic medications, including metformin, have been explored for their anticancer effects because of the substantial correlation between diabetes and cancer incidence. Metformin has recently gained interest for its anticancer effects against malignancies such as breast cancer, one of the leading causes of death among women worldwide. The cancer-related characteristics of cell proliferation, invasion, migration, and apoptosis are all targeted by metformin. Among breast cancer patients, triple-negative breast cancer (TNBC) is linked to an increased risk of early recurrence and metastases and has poor prognosis. In addition, TNBC has fewer treatment options compared to other breast cancer subtypes because it lacks hormone receptors and human epidermal growth factor receptor 2 (HER2), and it often develops resistance to available treatment options. The current review highlights the recent updates on the mechanistic insights and the efficacy of metformin and metformin-based approaches for the treatment of TNBC. We logically discuss the experimental evidence from the in vitro and in vivo studies exploring metformin’s effects on metabolic pathways, and then its combination with other therapeutic agents, targeting cell signaling pathways, and approaches to enhance metformin’s effects. We also present clinical studies that underscore the beneficial outcomes of metformin or its combination with other agents in TNBC patients. Full article
(This article belongs to the Special Issue Combination Therapy Approaches for Cancer Treatment)
Show Figures

Figure 1

22 pages, 10571 KiB  
Article
The Molecular Chaperone TCP1 Affects Carcinogenicity and Is a Potential Therapeutic Target for Acute Myeloid Leukemia
by Yong Wu, Guihui Tu, Yuxia Yuan, Jingwen Liu, Qingna Jiang, Yang Liu, Qiurong Wu, Lixian Wu and Yuanzhong Chen
Pharmaceutics 2025, 17(5), 557; https://doi.org/10.3390/pharmaceutics17050557 - 24 Apr 2025
Viewed by 163
Abstract
Background/Objectives: Acute myeloid leukemia (AML) is an aggressive malignancy marked by high relapse rates and molecular heterogeneity, necessitating the identification of novel therapeutic targets. T-complex protein 1 (TCP1), a chaperonin implicated in protein folding, remains underexplored in AML pathogenesis. This study investigates the [...] Read more.
Background/Objectives: Acute myeloid leukemia (AML) is an aggressive malignancy marked by high relapse rates and molecular heterogeneity, necessitating the identification of novel therapeutic targets. T-complex protein 1 (TCP1), a chaperonin implicated in protein folding, remains underexplored in AML pathogenesis. This study investigates the functional role of TCP1 in AML progression and evaluates its therapeutic potential. Methods: Using successive generations of xenografted tumor models, we systematically assessed the correlation between TCP1 expression and AML tumorigenicity. Functional consequences of TCP1 silence were evaluated through in vitro proliferation assays and in vivo tumor growth monitoring. Two distinct inhibitory strategies were employed: miR-340-5p-mediated transcriptional silencing and FTY720-induced disruption of TCP1 chaperone activity. Mechanistic insights were derived from ubiquitin–proteasome pathway analysis, cell cycle profiling, and apoptosis assays. Results: High TCP1 expression correlated strongly with enhanced AML tumorigenicity. Knockdown of TCP1 significantly inhibited AML cell growth and induced degradation of AML1-ETO and PLK1 proteins through the ubiquitin–proteasome pathway. miR-340-5p effectively silenced TCP1 expression, exhibiting an inverse correlation with TCP1 levels. FTY720 disrupted TCP1′s chaperone function, leading to cell cycle arrest, apoptosis, and reduced xenograft tumor growth in murine models. Conclusion: Our findings establish TCP1 as a promising therapeutic target for AML. Both miR-340-5p and FTY720 demonstrate potent anti-leukemic effects by suppressing TCP1 activity, highlighting their potential as novel strategies to inhibit AML proliferation and improve therapeutic outcomes. Full article
(This article belongs to the Section Drug Targeting and Design)
Show Figures

Graphical abstract

Previous Issue
Back to TopTop